To investigate whether MYC-targeted therapy could eliminate CSCs in HNSCC, we took advantage of the specific inhibitor of MYC, MYCi975, which has been shown to effectively inhibit MYC 24-26. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.